a pre-internet era, and describe how it felt to surf this interactome network in the absence of the sophisticated tools we have at our fingertips today.
By the time I left Belgium in January 1988 to join Rick Gaber's group, I had already worked on several yeast genetics projects with Franç ois Hilger, my PhD mentor. Although not terribly successful, these projects made me appreciate the beauty of the ''hide-and-seek'' games one can play with yeast. I became particularly fond of the concept of ''genetic selection,'' which consists of designing environmental and/or genetic conditions that prevent yeast cells from growing, and then selecting for mutations that circumvent the growth inhibitory conditions, as a way to identify genes and functions regulating such processes.
On my first day in the lab, Rick introduced me to a set of beautiful rpd mutants. Prior to setting up his own research group, Rick had worked in Gerry Fink's laboratory, where he had identified a gene called TRK1 and shown that it encodes a high-affinity transporter for potassium (K + ). Logically, trk1D cells require higher K + concentrations relative to their wild-type counterpart, and the hide-and-seek game of the Rpd selection scheme consisted of finding out how trk1D mutants can revert to allow growth on low K + concentrations.
I found that the two genes identified by recessive mutations, RPD1 and RPD3, genetically mapped at two new, previously undiscovered loci. This might not sound like a big deal today. But, at that time, it was very exciting because mapping mutations felt like planting flags in the genome to claim new territories. If no other gene had ever been mapped where you found your mutations, you had discovered a new gene and perhaps a novel function. In addition, as will become clear below, genetic mapping of new genes could more often than not help establishing functional connections between seemingly unrelated genes.
There was also a third group of dominant alleles among the rpd mutants, which we realized mapped very close to TRK2, the low-affinity K + transporter gene. In addition, wild-type TRK2 was required for the effect of both rpd1 and rpd3 on K + transport and rpd1 rpd3 double mutants did not show any synergy. In our 1990 Genetics paper describing the mutants, we concluded that ''RPD1 and RPD3 might function . in a single pathway or as subunits of a single negative regulator . required for the normal expression or activity of the low affinity K + transporter.'' Figuring out whether rpd mutations affected TRK2 by modulating its expression or the function of its product turned out to be of crucial importance. A set of experiments performed together with Ann Buckley, using a TRK2::lacZ reporter, suggested a modest, but reproducible effect on TRK2 expression.
But the story took an unexpected turn when I decided one day to try my luck with a quick phenotypic test. As I was plating my mutants, I noticed a stack of Petri plates containing sub-lethal concentrations of cycloheximide, an inhibitor of protein synthesis, that had been poured a few days earlier by someone else for an unrelated project. To this day, I have no idea what triggered my impulse to replica plate my crosses onto these plates, but I vividly remember my excitement when I opened the incubator the next morning and realized that the rpd mutants grew poorly or not at all on these plates. Importantly, the phenotype was only exhibited by rpd1 and rpd3, and not by TRK2 dominant mutants. This suggested that cycloheximide hypersensitivity might not be related to TRK2 function and that Rpd1 and Rpd3 might have a broader function and be involved in regulating other genes. From that point, I literally became obsessed with testing this possibility.
A possible global role for Rpd1 and Rpd3 was consistent with something unexpected I noticed while genetically mapping rpd1. It turns out that the closest gene to rpd1 known at that time was pho80. To precisely place rpd1 on the genetic map, I had to cross rpd1 and pho80 strains together. PHO80 is required for the transcriptional repression of PHO5, a gene encoding acid phosphatase that is repressed in high phosphate concentrations. While following the pho80 phenotype, I observed that rpd1 and rpd3 also increase the transcriptional levels of PHO5 under repression conditions. Again the effect was relatively small, on the order of two-fold, but it was reproducible and significant.
An even more rewarding connection was provided by a talk I heard from Randy Strich, then a postdoctoral fellow in Shelly Esposito's laboratory. He was describing the isolation of unscheduled ''These projects made me appreciate the beauty of the ''hide-andseek'' games one can play with yeast.'' meiosis or ''ume'' mutants based on the derepression of SPO13, a gene required for sporulation and normally tightly repressed in wild-type mitotic cells. At some point, he mentioned in passing that one of his mutants, ume4, mapped somewhere in the vicinity of rpd1. The connection was almost too beautiful to be true. I jumped to the podium at the end of his talk, and in a couple of minutes, we arranged how we were going to test whether rpd1 and ume4 mutations might reside in the same gene. The answer as we both expected was positive, which triggered an extremely fruitful collaboration.
The cloning and sequencing of RPD1, which altogether took close to a year and a half of hard work, provided yet another essential connection. Remember, this was before the yeast genome sequencing project, and it could often take years for two teams to realize they were working on the same gene. To speed things up, Mark Goebl at Indiana University had organized an informal database of unpublished yeast sequences. The system was simple. People would send him their sequences, he would compile them, and when matches were found between sequences obtained in different laboratories, he would inform the relevant parties. Lo and behold, Rick got a breathtaking call one day. Mark had spotted that RPD1 was identical to SIN3, a gene being sequenced in David Stillman's laboratory at the University of Utah.
Sin3 mutations had originally come out of screens independently performed in the laboratories of Ira Herskowitz and Kim Nasmyth, who were searching for SWI5-independent expression of an HO::lacZ fusion. HO is an endonuclease that is tightly repressed at the transcriptional level by a complex mechanism involving cell-cycle regulation and mother/daughter identity. It took us relatively little time to demonstrate the allelism between rpd1 and sin3 mutations, but since David published his SIN3 sequence about a year before we published our findings on RPD1, the name Sin3 is the most commonly used for the corresponding protein.
Randy Strich and I proceeded to demonstrate using a battery of lacZ fusions to other structural genes, as well as direct RNA level measurements, that sin3 mutations affect both transcriptional repression and activation of more than a dozen unrelated genes involved in functions as different as ion transport, acid phosphatase metabolism, cell-type regulation, and cell differentiation. In all cases tested, the phenotypes were nearly identical in rpd3 mutants. This was the support we needed to demonstrate that Rpd gene products were indeed global regulators of transcription.
However, the cloning and sequencing of the RPD3 gene failed to reveal anything informative. The translated Rpd3 protein sequence was novel and had no homology to any protein known at the time. I remember being very excited about having discovered a novel gene, but also being very depressed about not being able to find any domain or signature that could help us determine the biochemical function of the Rpd3 product. But of course in retrospect, it didn't matter at all since the Rpd3 sequence ended up being the key link that identified an in vivo role for HDAC.
After a rather painful attempt with another journal considered more prestigious, we ended up publishing these findings in two back-to-back papers in MCB in 1991. But even at MCB whose review process was well known to be professional and fair, it wasn't so easy to get the papers accepted. I recall that one reviewer was arguing that two-fold increases, as observed for most genes derepressed by sin3 and rpd3, could only be relevant to someone's salary, and would not likely correspond to anything important in biology.
The next question that we focused on was how Sin3 and Rpd3 might target the appropriate genes under various conditions to mediate their repression. We started by looking at the TRK2 dominant mutations, and to our surprise, found that they were localized at the TRK2 promoter, in a site similar to an upstream repressing sequence called URS1, originally identified by Terry Cooper's laboratory in the 1980s using a mutation located upstream of the CAR1 gene. CAR1 encodes arginase, the enzyme mediating the first step of the arginine catabolism pathway, and remarkably, this brings our story back to Belgium, my home country.
In the early 1960s, Marcelle Grenson and Jean-Marie Wiame's laboratory in Brussels had set out to understand the regulation of arginine biosynthesis and catabolism. In a genetic selection first ''This was before the yeast genome sequencing project, and it could often take years for two teams to realize they were working on the same gene.'' described in a meeting report of the Socie´te´belge de Biochimie in 1964, which the reader will remember, corresponds to the very year that Allfrey suggested his model, they described mutants affected in the repression of arginine biosynthesis. Oddly, these mutants also turned out to be affected in their ability to activate CAR1 under conditions triggering arginine catabolism, and this provided another hide-and-seek situation to select for mutations that would derepress CAR1. This is precisely how the original URS1 dominant mutation in CAR1 was found, in addition to recessive mutations in three separate trans-acting genes, two of which were later found by Evelyne Dubois and Francine Messenguy to be identical to SIN3 and RPD3.
This was a breathtaking loop of life for me. SIN3 and RPD3 were like my ''babies'' in graduate school, and when everything was said and done about them, it turned out that they had first seen the light of day in the 1970s, in my home country, just a few miles away from the place where I was born.
In the immediate aftermath of our findings on Sin3 and Rpd3, Randy Strich and Shelly Esposito, together with Evelyne Dubois and Francine Messenguy, demonstrated that the third gene identified in the Brussels mutant hunts was identical to UME6, another gene required for repression of SPO13 in mitotic cells. Importantly, it was demonstrated that Ume6 binds the URS1 site. This in turn strongly suggested that Ume6 recruits Sin3 and Rpd3 to their target promoters, at least at the SPO13 and CAR1 promoters, which immediately suggested a mechanism of specific recruitment to the appropriate promoters.
Our two 1991 MCB papers were soon followed by a publication in EMBO J by Tassos Georgakopoulos and George Thireos. While studying the GCN5 gene, which had been identified among general control non-derepressed or ''gcn'' mutants, Tassos and George made two important observations. First, Gcn5 was required for the ability of Gcn4, a well-known DNA binding transcription factor, to activate transcription in vivo. Second, Gcn5 also performed similar co-activation functions with other unrelated DNA binding transcriptional activators. The conclusion to be drawn from this was that Gcn5, too, was likely a global pleiotropic factor involved in transcriptional regulation.
In summary, starting in Brussels in 1964, the year Allfrey proposed his model of epigenetic regulation, yeast experiments intertwined in the most elaborate way possible led to a very dense network of molecular and genetic interactions almost as if, in retrospect at least, someone had planned every detail of the story from its very beginning. The Rpd3 and Gcn5 connections established by the Schreiber and Allis papers were literally a bombshell in the field of transcription, providing the basis for the so-called epigenetic revolution of the last two decades. They are and should be celebrated as such. But as one will immediately notice reading or rereading them, both papers could make their point without having to show any result on transcription per se. And that's what our genetic network contributed.
